6
Views
0
CrossRef citations to date
0
Altmetric
Original Article

Nesiritide in the management of treatment refractory pediatric heart failure

, &
Pages 101-107 | Received 06 Mar 2006, Published online: 04 Dec 2011

References

  • Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation 1996;94 (12): 3184–9.
  • Mills RM, LeJemtel TH, Horton DP, et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol 1999;34(1):155–62.
  • Burger AJ, Horton DP, LeJemtel T, et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventri-cular arrhythmias in the treatment of patients with acutelydecompensated congestive heart failure: the PRECEDENT study. Am Heart J 2002;144(6):1102–8.
  • Publication Committee for the VI. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial[see comment] [erratum appears in JAMA 2002;288(5):577]. JANIA 2002;287(12):1531–40.
  • Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005;111: 1487–91.
  • Sackner-Bernstein JD, Kowalski M, Fox M, et al. Short-term risk of death after treatment with nesiritide for decompen-sated heart failure: a pooled analysis of randomized controlled trials [see comment]. JANIA 2005;293(15):1900 –5.
  • Simsic JM, Reddy VS, Kanter KR, et al. Use of nesiritide (human B-type natriuretic peptide) in infants following cardiac surgery. Pediatr Cardiol 2004;25(6):668–70.
  • Smith T, Rosen DA, Russo P, et al. Nesiritide during extracorporeal membrane oxygenation. Pediatr Anesth 2005; 15(2):152–7.
  • Wheeler AD, Tobias JD. Nesiritide in a pediatric oncology patient with renal insufficiency and myocardial dysfunction following septic shock. Pediatr Hematol Oncol 2005;22:323–33.
  • Marshall J, Berkenbosch JW, Russo P, et al. Preliminary experience with nesiritide in the pediatric population. J Intensive Care Med 2004;19(3):164–70.
  • Feingold B, Law YM. Nesiritide use in pediatric patients with congestive heart failure. J Heart Lung Transpl 2004;23(12): 1455–9.
  • Mahle WT, Cuadrado AR, Kirshbom PM, et al. Initial experience with nesiritide in pediatric heart failure. J Am Coll Cardiol 2005;45 Suppl A:315A.
  • Jefferies JL, Denfield SW, Dreyer WJ, et al. A prospective evaluation of intravenous nesiritide in pediatric heart failure. J Am Coll Cardiol 2005;45(3):A1029–40.
  • Sehra R, Underwood K. Nesiritide use for critically ill children awaiting cardiac transplantation. Pediatr Cardiol 2006;27:47–50.
  • Mahle WT, Cuadrado AR, Kinhbom PM, et al. Nesiritide in infants and children with congestive heart failure. Pediatr Crit Care Med 2005;6(5):543–6.
  • Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decom-pensated congestive heart failure. Nesiritide Study Group [erratum appears in N Engl J Med 2000;343(20):1504]. N Engl J Med 2000;343(4):246–53.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.